Remove Drug Delivery Remove Drugs Remove Marketing
article thumbnail

Pharmaceutical drug delivery market and systems

Pharmaceutical Technology

Download our free, comprehensive list of the leading companies within the pharmaceutical drug delivery market.

article thumbnail

Gelteq IPO: Supporting Gel Technology for Oral Drug Delivery

XTalks

per share, the offering included 1,300,000 ordinary shares, which began trading on the Nasdaq Global Market under the ticker symbol GELS on October 29, 2024. In the pharmaceutical segment, Gelteq advances its lead product — a gel-based pain management therapy — through the US Food and Drug Administration (FDA)’s 505(b)(2) pathway.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Polyrizon IPO Strengthens Momentum in Non-Invasive Drug Delivery Solutions

XTalks

Trading began on the Nasdaq Capital Market under the ticker “PLRZ” on October 29, 2024. Its lead candidate, PL-14, targets nasal allergies and is scheduled for US Food and Drug Administration (FDA) submission via the 510(k) pathway, with preclinical trials expected to start in the second quarter of 2025 and pivotal trials by the end of 2025.

article thumbnail

IoT innovation: Leading companies in nanoparticles for drug delivery

Pharmaceutical Technology

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Key innovation: Leading companies in nanoparticles for drug delivery. Bristol-Myers Squibb is the leading patent filer in nanoparticles for drug delivery.

article thumbnail

FDA Releases Draft Guidance on Essential Drug Delivery Outputs

FDA Law Blog

Lenz, Principal Medical Device Regulation Expert — For several years, FDA has requested that sponsors of drug or biologic led combination products identify essential performance requirements (EPRs) related to the device constituent in their applications. By Adrienne R. does not use this term.

article thumbnail

Subcutaneous Medications and Drug Delivery Systems

Roots Analysis

Biologics constitute a majority of the top selling drugs and represent one of the fastest growing segments of the overall pharmaceutical industry. In fact, the share of biologics in the overall pharmaceutical contract manufacturing market has increased from 16% in 2006 to over 25% in 2017.

article thumbnail

Intracellular Drug Delivery – Future Potential

Roots Analysis

Hence, a precision therapy or we can say a target therapy (involving intracellular drug delivery) is much needed to all the patients suffering from cancer. Here is how the intracellular drug delivery comes into action for majority of the fatal diseases that requires target therapy. The answer is yes. The answer is yes.